San Antonio Breast Cancer Symposium – Talk Bio

Actionable Insights Powered by AI

Roche breast cancer pill cuts post-surgery recurrence risk by 30% in major trial

1 month ago talkbio0Tagged Adjuvant Therapy, Disease-Free Survival, ER-positive, giredestrant, HER2-negative, hormone receptor-positive, Hormone Therapy, Malignant neoplasm of breast, Oral SERD, phase III lidERA trial, Recurrence Risk, Roche (company), San Antonio Breast Cancer Symposium

Roche; giredestrant; breast cancer; hormone receptor-positive; ER-positive; HER2-negative; oral SERD; endocrine therapy; adjuvant therapy; recurrence risk; phase III lidERA trial; disease-free survival; San Antonio Breast Cancer Symposium

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Data in Leptomeningeal Metastases at SABCS 2025

2 months ago talkbio0Tagged central nervous system cancers, Dosage, Escalation, Metastatic Malignant Neoplasm to the Leptomeninges, Phase 1 (qualifier value), Plus Therapeutics, poster spotlight, ReSPECT-LM, REYOBIQ, SABCS, San Antonio Breast Cancer Symposium, Therapeutic radiology procedure

Plus Therapeutics; ReSPECT-LM; Phase 1; dose escalation; REYOBIQ; leptomeningeal metastases; San Antonio Breast Cancer Symposium; SABCS 2025; poster spotlight; central nervous system cancers; radiotherapeutics